The company has not filed an annual or quarterly report since its Q3 FY2020 10-Q, filed Nov 5, 2020. Its latest SEC filing is a 15-12B from Nov 27, 2020.
10-Q for Q3 FY2020, filed Nov 5, 2020
The sections below describe the company as of the FY2019 annual report.
Develops small-molecule therapies for serious heart diseases, including hypertrophic and dilated cardiomyopathy, for patients with specific disease characteristics.
10-K for FY2019, filed Feb 27, 2020We are a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted…View ↗
Since our inception in 2012, we have generated a robust pipeline of small molecules that target diseases of the heart muscle, or…View ↗
In addition to mavacamten, we have generated the following programs to address a variety of disruptions in heart muscle contraction and…View ↗
Danicamtiv (formally MYK-491) is our orally-administered small molecule designed to increase cardiac contractility without impairing…View ↗
MYK-224 is our second small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation. MYK-224 is…View ↗
The company planned to market its initial heart-disease products through a dedicated sales force focused on specialist and targeted cardiologists, including physicians at academic institutions, hospitals, medical centers and community practices.
10-K for FY2019, filed Feb 27, 2020We believe that we can maximize the value of our products by retaining substantial commercialization rights to our product candidates and…View ↗
Our current strategy is to market our initial HCM and DCM products using a dedicated, direct sales force focused on cardiomyopathy…View ↗
We are initially pursuing market approval and commercialization in the U.S. We have also begun hiring a team based in Europe to evaluate…View ↗
10-Q for Q3 FY2020, filed Nov 5, 2020
−$84.7MView ↗
8-K, filed Nov 17, 2020
As described in the Introductory Note above, on November 17, 2020, Merger Sub irrevocably accepted for payment all shares of Company Common…View ↗
Broader cardiovascular focus
The earlier report focused on rare, heritable cardiomyopathies, while the latest describes work spanning serious cardiovascular diseases, including additional heart-failure populations.
10-K for FY2016, filed Mar 13, 2017 10-K for FY2019, filed Feb 27, 2020MyoKardia, Inc. (the “Company”), incorporated under the laws of the State of Delaware in 2012, is a clinical stage biopharmaceutical…View ↗
We are a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted…View ↗
Based on evidence generated from clinical and preclinical studies, we tested mavacamten in our Phase 2 MAVERICK-HCM study, which enrolled…View ↗
Danicamtiv (formally MYK-491) is our orally-administered small molecule designed to increase cardiac contractility without impairing…View ↗
LUS-1 is intended to counteract muscle abnormalities that result in impaired relaxation of the left ventricle, without decreasing…View ↗
Competes with Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, C.H. Boehringer Sohn, Eli Lilly, Novartis, Takeda Pharmaceutical, Cytokinetics, Pfizer, Tenaya Therapeutics, Berlin Cures, and Zensun (Shanghai) Sci. & Tech.
10-K for FY2019, filed Feb 27, 2020In the field of heart failure drug development, our principal competitors include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers…View ↗
Loading...
